Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.54 USD | -1.28% | -.--% | +79.28% |
Business Summary
Number of employees: 138
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Woodhouse
CEO | Chief Executive Officer | 54 | 15-03-01 |
William Rieflin
CHM | Chairman | 64 | 10-08-31 |
Daniel Kaplan
CTO | Chief Tech/Sci/R&D Officer | - | 07-12-31 |
William Chang
CTO | Chief Tech/Sci/R&D Officer | - | 19-01-31 |
Hsiao Lieu
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-02-28 |
Valerie Pierce
CMP | Compliance Officer | 61 | 19-10-28 |
David Goeddel
BRD | Director/Board Member | 72 | 07-12-31 |
Joyce Q. Acbay
LAW | General Counsel | - | 20-03-31 |
Irene Perlich
AUD | Comptroller/Controller/Auditor | - | 21-02-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Roger Perlmutter
BRD | Director/Board Member | 71 | 21-06-07 |
David Goeddel
BRD | Director/Board Member | 72 | 07-12-31 |
William Rieflin
CHM | Chairman | 64 | 10-08-31 |
David Woodhouse
CEO | Chief Executive Officer | 54 | 15-03-01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 83,462,408 | 81,886,322 ( 98.11 %) | 0 | 98.11 % |
Company contact information
NGM Biopharmaceuticals, Inc.
333 Oyster Point Boulevard
94080-7014, South San Francisco
+650 243 5555
http://www.ngmbio.comSector
1st Jan change | Capi. | |
---|---|---|
+79.28% | 129M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- NGM Stock
- Company NGM Biopharmaceuticals, Inc.